Fundraising Fox

GreenJay Therapeutics

Houston, US · Founded 2022 · 1 known investors

GreenJay Therapeutics is a late-stage pharmaceutical company reformulating existing drugs to improve clinical outcomes for hematological diseases. Its lead product, Bulanta, is a new intravenous busulfan formulation that removes a Class 2 solvent to reduce toxicity, initially targeting chronic myelogenous leukemia patients undergoing stem cell transplantation.

BiotechHealthtech

Founders & leadership

TL
Tommy LeeNamed on SEC filing
MT
Michael Thomas RedmanNamed on SEC filing
BA
Borje AnderssonNamed on SEC filing
JD
James Donald PayneNamed on SEC filing
VT
Vassil TzenovVice President & Chief Financial Officer
DP
Donald PayneCEO (deceased)

Investors · 1

Central Texas Angel NetworkAustin

Reported raises · per SEC filings

Form D private placements

$1M disclosed across 1 of 2 rounds · 2023–2024

▶$1MofferedApr 2024 · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Tommy L LeeDirector
  • Borje S AnderssonDirector
  • Michael T RedmanDirector
  • James Donald PayneExecutive Officer
Offering amount
$1M
Minimum investment
$10K
Incorporated
Corporation, Delaware, 2022
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1MraisedJun 2023 · 27 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Tommy LeeDirector
  • Michael Thomas RedmanExecutive Officer, Director
  • Borje AnderssonDirector
  • James Donald PayneExecutive Officer
Offering amount
$1M
Amount sold
$1M
Minimum investment
$5K
First sale
Jan 2023
Incorporated
Corporation, Delaware, 2022
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does GreenJay Therapeutics do?
GreenJay Therapeutics is a late-stage pharmaceutical company reformulating existing drugs to improve clinical outcomes for hematological diseases. Its lead product, Bulanta, is a new intravenous busulfan formulation that removes a Class 2 solvent to reduce toxicity, initially targeting chronic myelogenous leukemia patients undergoing stem cell transplantation.
Who are GreenJay Therapeutics's investors?
GreenJay Therapeutics's investors include Central Texas Angel Network.
How much funding has GreenJay Therapeutics raised?
GreenJay Therapeutics has disclosed $1M raised across 1 of its 2 known rounds.
Where is GreenJay Therapeutics headquartered?
GreenJay Therapeutics is headquartered in Houston, US.